Recent Updates
Recently added Catalysts
PTN Positive Sentiment Score: 70/100

Palatin to Present at the H.C. Wainwright 25 th Annual Global Investment Conference Cranbury, NJ

Key Takeaway: Palatin Technologies, Inc. has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference scheduled for September 11-13, 2023, in New York. Management will present on September 13 at 10:00 a.m. ET, accompanied by a live webcast. The presentation focuses on their development of medicines based on molecules that modulate melanocortin receptor systems, aiming for treatments for diseases with significant unmet needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Palatin will present at a significant investment conference, showcasing their work.
  • The company develops first-in-class medicines addressing unmet medical needs.
  • Palatin's strategy includes forming collaborations with industry leaders to enhance commercial potential.

Full Press Release Details

ptn_ex991.htm EXHIBIT 99.1
Palatin to Present at the H.C. Wainwright
25th Annual Global Investment Conference
Cranbury, NJ, September 7, 2023 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.
The Company presentation will be held on Wednesday, September 13, 2023 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Investors section of Palatin's website at http://www.palatin.com. A replay of the webcast will be available for 30 days following the presentation.
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Investor Inquiries: Media Inquiries:
Stephen T. Wills, CPA, MST Paul Arndt, MBA, LifeSci Advisors
CFO/COO (609) 495-2200 Managing Director (646) 597-6992
Info@Palatin.com Paul@LifeSciAdvisors.com

Frequently Asked Questions

When is Palatin's presentation at the H.C. Wainwright conference?

Palatin's presentation will occur on September 13, 2023, at 10:00 a.m. ET.

How can I watch Palatin’s conference presentation?

The presentation will be available via a live webcast on Palatin's website.

What is Palatin Technologies focused on developing?

Palatin develops first-in-class medicines that modulate the melanocortin receptor system.

What type of collaborations does Palatin pursue?

Palatin seeks marketing collaborations with industry leaders to enhance commercial potential.

Where can I find more information about Palatin?

Visit Palatin's website at www.palatin.com or follow them on Twitter.

Last updated: Sep 7, 2023